Fig. 4

Receiver operating characteristic curves (ROC) illustrating the predictive performance of the radiomics signature for immunotherapy response in the ZZU (a) and SDU cohorts (b). Radscore distribution for different immunotherapy responses in the ZZU (c) and SDU cohorts (d). Kaplan-Meier analysis of progression-free survival (PFS) and overall survival (OS) based on distinct radscore groups in the immunotherapy cohorts: (e) PFS stratified by radscore groups in the ZZU cohort; (f) OS stratified by radscore groups in the ZZU cohort; (g) PFS stratified by radscore groups in the SDU cohort; (h) OS stratified by radscore groups in the SDU cohort. CR = complete response, PR = partial response, SD = stable disease, PD = progressive disease